CClinicalTrials.gg
RecruitingNCT04829357Updated Jul 6, 2026

Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System

An observational study in Stress Urinary Incontinence, sponsored by Ethicon, Inc.. Recruiting at 4 sites in 3 countries. Open to female participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Ethicon, Inc. · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
195
Ages
21 Years and older
Sex
Female
01

Study summary

The objective of this single arm, post market, clinical study is to evaluate the performance of Gynecare TVT ABBREVO® Continence System in women undergoing Mid-urethral sling surgery for Stress Urinary Incontinence (SUI).

02

Conditions studied

  • Stress Urinary Incontinence

Keywords

  • Gynecare TVT ABBREVO® Continence System
  • SUI
03

Who can participate

Ages eligible
21 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Female subjects ≥ 21 years of age with a diagnosis of SUI, resulting from urethral hypermobility and/or intrinsic sphincter deficiency

Inclusion criteria

Subjects who satisfy all of the following criteria will be considered eligible for enrollment in this study:

  1. Stress urinary incontinence symptoms
  2. Diagnostic evaluation, a positive cough stress rest, to confirm diagnosis of stress urinary incontinence.
  3. Female subjects ≥ 21 years of age requiring treatment of SUI
  4. Desired surgical correction of stress urinary incontinence using synthetic sub-urethral vaginal slings
  5. Planned surgery for primary stress incontinence without concomitant prolapse surgery
  6. Patient able and willing to participate in follow-up
  7. Subject or authorized representative has signed the approved informed consent

Exclusion criteria

Exclusion Criteria

Subjects meeting any of the following criteria will be considered not eligible for enrollment in this study:

  1. Physical or psychological condition which would impair study participation or are unwilling or unable to participate in all required study visits and are unable to complete the questionnaires
  2. Any pre-operative or intra-operative findings identified by the surgeon that may preclude the use of study product
  3. History of previous synthetic, biologic or fascial sub-urethral sling
  4. Pregnancy or plans for future pregnancy
  5. History of bleeding diathesis or current anti-coagulation therapy which cannot be suspended peri-operatively according to site's standard practice.
  6. Current genitourinary fistula or urethral diverticulum
  7. Reversible cause of incontinence (i.e. drug effect)
  8. Contraindication to surgery
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
195 participants (estimated)
Patient registry
No

Interventions

  • DeviceIntervention

    There is no intervention, beyond necessary clinical care, in this study. The surgical procedures being performed within the study are identical to the surgical procedures the subjects would receive as part of SOC.

05

What researchers measure

Primary outcomes

  1. Cough Stress Test (CST) Assessment Change

    Objective cure of Stress Urinary Incontinence (SUI) (treatment success) approximately 5-10 years after surgery, defined as a negative CST

    Time frame: Post-surgery through study completion, approximately 5-10 yrs

Secondary outcomes

  1. Patient Global Impression of Improvement (PGI-I)

    Time frame: Post-surgery through study completion, approximately 10 yrs

  2. International Consultation on Incontinence Questionnaire- Urinary Incontinence Short Form (ICIQ-UI SF)

    Time frame: Baseline and post-surgery through study completion, approximately 10 yrs

  3. Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12)

    Time frame: Baseline and post-surgery through study completion, approximately 10 yrs

  4. Wong-Baker FACES® Pain Rating Scale

    To assess pain on a scale from 0 (no pain) to 10 (worst pain) related to study device or procedure.

    Time frame: Post-surgery through study completion, approximately 10 yrs

06

Study locations

4 of 4 sites recruiting
  • Institute for Female Pelvic Medicine
    North Wales, Pennsylvania 19454, United States
    Recruiting
  • Bio-Medical University Rome
    Rome, Italy
    Recruiting
  • Ospedale San Pietro Fatebenefratelli
    Rome, Italy
    Recruiting
  • Ospedale Regionale Beata Vergine
    Mendrisio, Switzerland
    Recruiting
07

References and documents

Individual participant data

Plan to share: Yes — Johnson \& Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT04829357
Lead sponsor
Ethicon, Inc.
Responsible party
Sponsor
First posted
Apr 2, 2021
Start date
Sep 9, 2021
Primary completion
Dec 31, 2033 (estimated)
Completion
Dec 31, 2038 (estimated)
Last update
Jul 6, 2026

Study contacts

Christine Romanowski
Contact
cromanow@its.jnj.com
908-808-6219
Martin Weisberg, MD
study director · Ethicon, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion